Olaparib, a PARP1 inhibitor, is now approved for patients with advanced ovarian cancer harboring BRCA1 or BRCA2 deleterious mutations, as loss of BRCA sensitizes these tumors to further inhibition of DNA repair and results in a synthetic lethality [19, 20]. Here, BRCA2 is linked to ovarian cancer.